SCHEMBL4211218

SCHEMBL4211218

CCOC(=Cc1ccc(-c2cccc(N(C)C(=O)NCCc3ccc(OC)cc3)c2)cc1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
GLA P06280 1/20 0.44
LMNA P02545 5/20 0.40
PLAAT3 P53816 1/20 0.39
PLAAT5 Q96KN8 1/20 0.39
PLAAT2 Q9NWW9 1/20 0.39
PLAAT4 Q9UL19 1/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.39
ATM Q13315 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
CAPN1 P07384 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
FPR2 P25090 1/20 0.38
MTNR1A P48039 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4218382 1.00 KMT2A (0.44) KMT2AGLALMNAPLAAT3PLAAT5
SCHEMBL4211214 1.00 KMT2A (0.44) KMT2AGLALMNAPLAAT3PLAAT5
SCHEMBL4211364 0.92 PLAAT3 (0.43) KMT2ALMNAPLAAT3PLAAT5PLAAT2
SCHEMBL4211353 0.92 PLAAT3 (0.43) KMT2ALMNAPLAAT3PLAAT5PLAAT2
SCHEMBL4211359 0.92 PLAAT3 (0.43) KMT2ALMNAPLAAT3PLAAT5PLAAT2
SCHEMBL4211215 0.88 CAPN1 (0.46) KMT2ALMNAPLAAT3PLAAT5PLAAT2
SCHEMBL4220446 0.87 LMNA (0.39) KMT2ALMNAPLAAT3PLAAT5PLAAT2
SCHEMBL4220441 0.87 LMNA (0.39) KMT2ALMNAPLAAT3PLAAT5PLAAT2
SCHEMBL4220448 0.87 LMNA (0.39) KMT2ALMNAPLAAT3PLAAT5PLAAT2
SCHEMBL4209360 0.86 PLAAT3 (0.45) KMT2ALMNAPLAAT3PLAAT5PLAAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US claimed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US claimed
US-8383652-B2 Biaromatic compounds that modulate PPAR-receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-26 US disclosed
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-01-08 US disclosed
EP-1943213-A2 PPAR MODULATING BIAROMATIC COMPOUNDS Galderma Research & Development (FR) 2008-07-16 EP disclosed
WO-2007049158-A2 PPAR MODULATING BIAROMATIC COMPOUNDS GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012129-A1 NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS PPARG, PPARD, PPARA KMT2A 2532/4885GLA 729/4885LMNA 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.